ArticleDrug testing and analysis2026
Investigation of the In Vitro and In Vivo Metabolism and μ-Opioid Receptor Affinity of the Nitazene N-Pyrrolidino Fluetonitazene.
Article in Drug testing and analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
N-pyrrolidino fluetonitazene (N-pyrrolidino-4'-(2-fluoroethoxy) nitazene) also known as fluetonitazepyne, is the fluorinated analogue of etonitazepyne, belonging to the group of new synthetic opioids (NSOs), which are among the fastest-growing classes of new psychoactive substances. In the present study, the N-pyrrolidino fluetonitazene metabolism was investigated in vitro using pooled human liver microJsomes (pHLM) and in authentic samples from a forensic postmortem case. Qualitative analysis was performed using liquid chromatography-high-resolution tandem mass spectrometry (LC-HR-MS/MS). Confirmation and semiquantitative analysis of N-pyrrolidino fluetonitazene in urine and blood were carried out using liquid chromatography tandem mass spectrometry (LC-MS/MS). The μ-opioid (MOR) receptor affinity of N-pyrrolidino fluetonitazene was determined using an LC-MS/MS-based competitive binding assay. In total, eight different metabolites for N-pyrrolidino fluetonitazene were tentatively identified in vitro in pHLM incubations of which three (M2 O-dealkylation, M6 oxidative deamination and M8 carboxylation to N-butanoic acid) were also found in the postmortem urine sample. In the blood samples, only one metabolite was found (M9 formed by N-acetylation of 5-aminofluetodesnitazene). This metabolite was only observed in the in vivo samples and was the most abundant metabolite in blood and urine samples. We also detected metabolite M2 (formed by 4'-hydroxylation), which is common in the metabolism of other nitazepyne-type substances. For the confirmation of N-pyrrolidino fluetonitazene, we recommend including M8 and M9 as analytical target compounds, since they are specific N-pyrrolidino fluetonitazene metabolites. Furthermore, we demonstrated that the LC-MS/MS-based MOR receptor affinity assay yields valid results for N-pyrrolidino fluetonitazene that are consistent with those obtained using established radioligand-based methods.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.